Retroscreen Partners with ERT for Centralized ECG Services in hVIVO Challenge Studies - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Retroscreen Partners with ERT for Centralized ECG Services in hVIVO Challenge Studies

Source: Company News Release

Retroscreen Virology Group plc (AIM: RVG), the pioneer of hVIVO Human Challenge Models (“HCMs”) selects ERT as a partner to improve the cardiac safety of its study volunteers, further reinforcing the scientific integrity of the Company’s pioneering biomedical research and development platform.

Retroscreen has today announced a strategic partnership with ERT to administer ERT’s proven centralised Electrocardiogram (ECG) solution and services to ensure the cardiac safety of volunteers participating in its ground-breaking human challenge studies. The centralised ECG solution includes ERT’s proprietary EXPERT® operating platform, which delivers complete and efficient cardiac safety study management and reporting, thereby assisting Retroscreen’s mission to accelerate and reduce the cost of bringing new therapeutics and diagnostics to market.

Amy Furlong, Executive Vice President and Product Line Executive, Cardiac and Enterprise Solutions, ERT commented “ERT shares a common objective with Retroscreen in our commitment to offer innovative solutions that deliver the highest standards of care for study participants. We look forward to a long and successful partnership as we integrate our EXPERT and hVIVO platforms to support the ground-breaking research and development of new therapies and diagnostics.”

Dr. Martin Johnson, Senior Medical Director at Retroscreen commented “Volunteer care and medical integrity are cornerstones of the pioneering work we do in the field of human challenge studies. Retroscreen is delighted to partner with ERT and looks forward to realising significant benefits from its centralised ECG solution, including even higher levels of volunteer and patient care, and continuing regulatory conformance.”

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
86%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
7%
View Results
Untitled Document
Source: Company News Release,
Click here